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httpcense.Abstract Background: Ventilator associated pneumonia (VAP) is a dynamic disease caused by a
wide spectrum of pathogens and associated with morbidity and mortality.
Purpose: The study concerned with an analysis of VAP studies done in Egyptian University Hos-
pitals in the last 10 years to describe the magnitude of the problem of VAP as a complication of
mechanical ventilation, and to explore its predictors and most common causative organisms.
Methods: To identify relevant published studies we searched the medical literature for articles
done in Egypt published during the past 10 years, using midline PubMed and Google scholar, where
the full text articles were downloaded. We also searched the thesis discussed and passed (Registered)
at the website of the Egyptian Universities libraries consortium visiting the website of the supreme
council of Egyptian Universities.
Results: Most of the 37 studies on which analysis were done were concerned with the risk fac-
tors, causative organisms, and incidence. The most common risk factors were leukopenia, throm-
bocytopenia, high CRP, metabolic acidosis, nasal endotracheal intubation, re-intubation, prior
antibiotic use, and contaminated ICU environment with lack of infection control measures, use
of antacids and H2 blocker, corticosteroids use, and coma. The most common causative organisms
were Pseudomonas aerogenosa, Klebsiella, Escherichia coli, Staphylococcus aureus, Acinetobacter,
Candida and Proteus.00700390.
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18 A. Fathy et al.Conclusion: It is important to establish large-scale multi center national studies to explore inci-
dence of VAP, all possible risk factors (whether preventable or non preventable), causative organ-
isms, and mortality due to VAP and its economic aspect.
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Ventilator-associated pneumonia (VAP) is deﬁned as nosoco-
mial pneumonia in mechanically ventilated patients which
develops more than 48 h after initiation of mechanical ventila-
tion (MV). VAP is divided into early onset VAP which occurs
within 5 days of mechanical ventilation and late onset VAP
which develops ﬁve or more days after initiation of mechanical
ventilation. The importance of segregating VAP into early and
late is that, the pathogenesis, microorganisms responsible and
outcome in these two groups are different and so the therapeu-
tic implications also differ (1).
VAP arises when there is bacterial invasion of the pulmon-
ary parenchyma in a patient receiving mechanical ventilation.
Inoculation of the formerly sterile lower respiratory tract typ-
ically arises from aspiration of secretions, colonization of the
aerodigestive tract, or use of contaminated equipment or med-
ications. Risk factors for VAP include prolonged intubation,
enteral feeding, witnessed aspiration, paralytic agents, underly-
ing illness and extremes of age (2).
The risk factors for VAP can be divided into three catego-
ries: host related, device related, and personnel related. Host-
related risk factors include preexisting conditions such as
immunosuppression, chronic obstructive lung disease, and
acute respiratory distress syndrome. Other host-related factors
include patients’ body positioning, level of consciousness,
number of intubations, and medications, including sedative
agents and antibiotics (3).
The pathogenesis of ventilator-associated pneumonia usu-
ally requires two important processes to take place: bacterial
colonization of the aerodigestive tract and the aspiration of
contaminated secretions into the lower airway (4).
The diagnosis of VAP is a clinical suspicion. The most ac-
cepted clinical deﬁnition for suspicion of pneumonia is cur-
rently the presence of a pulmonary inﬁltrate on chest
radiograph plus two of the following three criteria: leukocyto-
sis or leukopenia, purulent respiratory secretions and fever or
hypothermia. This approach has good sensitivity but poor
speciﬁcity and the next step is to obtain samples of the lower
respiratory tract for microbiological tests (5).
Since VAP is a critical and life saving issue in ICU, and
there were little studies handling this important infection, with
seldom little or no analysis or speciﬁc data reported about it,
we did this systematic review study analyzing VAP studies
done in Egyptian University Hospitals in the last 10 years to
describe the magnitude of the problem of VAP in Egypt
exploring its predictors and its most common causative
organisms.Methodological approach
This analysis includes both narrative review and systematic
review.Narrative review
Data concerning VAP were collected from published reviews,
original research, editorials and textbooks. Literatures were
identiﬁed through computer-based search from relevant search
websites and electronic data bases (e.g. PubMed and Google
scholar) and hand-based search in medical libraries. Only liter-
atures written in English were included.
Systematic review
Search strategy (literature search)
To identify the relevant analysis, we searched the thesis dis-
cussed and passed (Registered) at the website of the Egyptian
Universities libraries consortium (http://www.mans.edu e.g.)
visiting the website of the supreme council of Egyptian Univer-
sities. To identify relevant published studies we searched the
medical literature for articles published during the past
10 years, using midline PubMed and Google scholar, where
the full text articles were downloaded.
Study selection
All studies with VAP in the title were included, whether
descriptive, analytic or interventional in design. To be included
in the review studies have to cite any of the following:
(1) Incidence/prevalence of VAP.
(2) Risk factors of VAP.
(3) Causative organisms of VAP.
Data abstraction
The abstracted data included the name of university, investiga-
tor/author, year of publication/acceptance of thesis, study de-
sign, age of study population, sample size, incidence of VAP,
risk factors and causative organisms. Study design was judged
and evaluated by the supervisors.
Results
By searching different web sites besides visiting the libraries of
some of the Egyptian Universities we collected the material of
our study. We searched the Website of Mansoura University,
visiting the website of the supreme council of Egyptian Univer-
sities and then Egyptian Universities Libraries Consortium. By
visiting the libraries of some Egyptian Universities we found
31 studies on VAP.
Then we searched PubMed, Google and Google Scholar
sites with titles VAP in Egypt and Analysis of VAP, we found
six scientiﬁc researches of VAP in Egypt in three Egyptian
Table 1 Incidence/proportion of VAP in Egyptian University hospitals.
University Author No. of patients Age group Design Incidence
Mansoura Abd El-Kader
[1]
97 1 month–18 ys. Descriptive cross
sectional study
22.6%
Ain Shams Abd El-Kader
[2]
40 1–8 ys. Descriptive cross
sectional study
75%
Alexandria Soliman [3] 75
*3 groups
- Normal saline
- CHX
- CHX/COL
19–75 ys. Interventional study Over all 33.3%
 N.saline = 52.0%
 CHX= 28.0%
 CHX/COL= 20.0%
Ain Shams Abdel-Gawad
et al. [4]
252 Mean age;
16.6 ± 20.5
month
Cohort prospective
study
50%
Alexandria Tayel [5] 110 Neonates
(2–8 days)
Cross sectional
descriptive study
68.1%
Alexandria Abou El-Abbas
[6]
206 1–75 ys. Descriptive cross
sectional study
16%
Alexandria Khamis [7] 60 HME= 30 and
HH= 30
16–77 ys. Interventional
study
HME= 56.7%
HH= 63.3%
Ain Shams Mohammed [8] 107 18–75 ys. Descriptive cross
sectional study
55.1%
CHX, chlorhexidine; HME, heat moisture exchanger.
CHX/COL, chlorhexidine/colistin; HH, heated humidiﬁer.
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studies are as the following, 28 studies were thesis, three studies
were essay and six studies were researches/papers and pub-
lished in scientiﬁc journals. We already had 33 studies from
37 which were potentially legible for analysis. Four studies
were not found in the libraries. From the 33 studies 17 studies
were included in our study and 16 studies were excluded for
different reasons as being essay, intervention study concerning
other aspects of VAP.
The point of view of every study was exactly the methodol-
ogy and the result as regards the causative organisms, risk fac-
tors and incidence of VAP. The 17 studies were sorted as the
following: nine studies concerned with the causative organisms
of VAP (with two studies from them concerned also with risk
factors), eight studies concerned with incidence and causative
organisms (with two studies from them concerned also with risk
factors).
Table 1 shows the incidence/proportion of VAP in Egyp-
tian University hospitals. The age of the patients ranged from
2 days to 77 years. Eight studies concerned with incidence of
VAP in three Universities; Alexandria (four studies), Ain
Shams (three studies) and Mansoura (one study). Incidence
of VAP ranged from 16% to 75%, with the lowest ratio in
Alexandria and the highest one in Ain Shams University. Five
of the studies were descriptive cross sectional, with two inter-
ventional and one cohort prospective study.
As regards risk factors of VAP, there were three descriptive
cross sectional studies in Mansoura (two studies) and Alexan-
dria (one study) and one case control study in Tanta University,
in Pediatrics and adults explored the risk factors of VAP. The
study of Tayel [5] in Alexandria University in Neonates (2–
8 days) concluded the most common risk factors of VAP were
gestational age less than 33.3 weeks, birth weight less than
1.405 kg, leukopenia, thrombocytopenia, high CRP and meta-
bolic acidosis. The second study of Shalaby [10] in TantaUniversity in Neonatal and Pediatric ICU at Tanta University
concluded the most common risk factors of VAP as nasal endo-
tracheal tubes, re-intubation, prior antibiotic use, colonized
health care workers with MRSA and contaminated ICU de-
vices. The third study of Seweilam [9] in Mansoura University,
identiﬁed the risk factors as the following; prior antibiotic use,
duration of mechanical ventilation, reintubation, use of antac-
ids and H2 blockers, corticosteroids use and coma. The fourth
study of Abd El-Kader [1] in Mansoura University reported
that long duration of pediatric ICU admission (more than
17 days) and long duration of mechanical ventilation (more
than 12 days) are the risk factors of VAP as in Table 2.
As regards the causative organisms of VAP, 17 studies were
concerned; 10 in Alexandria, three in Mansoura, three in Ain
Shams and one in Tanta Universities. Most of the studies were
descriptive cross sectional; 10 studies, with four interventional
studies, two case control studies and one cohort prospective
study. Age ranged from 1 day to 85 years. The samples were
ETA, BAL, sputum and throat swab.
From the previous tables (Table 1,2,3) we observed that the
most common causative organisms were Pseudomonas
aerogenosa, Klebsiella, Escherichia coli, Staphylococcus aureus,
Acinetobacter, Candida and Proteus followed by MRSA,
Streptococci, Polymicrobial, Coagulase Neg. Staph., VRSA,
OSSA, ORSA, Citrobacter, MSSA, Gm ve NLF, Enterobac-
ter aerogenosa, Diphtheria and Enterococcus fecalis. The most
common causative organisms were gram negative bacilli, gram
positive cocci and gram negative enteric cocci and mostly
MDR pathogens.
Discussion
Ventilator associated pneumonia is a dynamic disease caused by
a wide spectrum of pathogens and associated with morbidity
andmortality. It accounts for up to 60%of all Healthcare-Asso-
Table 2 Risk factors associated with VAP in Egyptian Universities.
University Author No. of patients Age group Design Risk factors
Mansoura Abd El-Kader [1] 97 1 month–18 ys. Descriptive cross
sectional study
1. Long duration of pediatric ICU admission
(more than 17 days)
2. Long duration of mechanical ventilation
(more than 12 days)
Mansoura Seweilam [9] 95 1–85 ys. Descriptive cross
sectional study
1. Prior antibiotic use
2. Duration of mechanical ventilation
3. Reintubation
4. Use of antacids and H2 blockers
5. Corticosteroids use
6. Coma
Tanta Shalaby [10] 52 (42: cases, 10: control) 1 day–18 ys. Case control study 1. Nasal endotracheal tubes
2. Re-intubation
3. Prior antibiotic use
4. Colonized health care workers with MRSA
5. Contaminated ICU devices
20 A. Fathy et al.ciated Infections, 10–28% of critical care patients and increases
length of ICU stay by 28% [21]. Prevalence estimates of VAP
vary between 6 and 52 cases per 100 patients, depending on
the population studied (Joseph et al., 2010).
In order to appropriately categorize the causative agent or
mechanism it is usually recommended to obtain a culture prior
to initiating mechanical ventilation as a reference. As such,
many of the typical symptoms of pneumonia will either be ab-
sent or unable to be obtained. Two strategies exist for diagnos-
ing VAP. One strategy collects cultures from the trachea of
people with symptoms of VAP plus a new or expanding inﬁl-
trate on chest X-ray. The other is more invasive and advocates
a bronchoscopy plus bronchoalveolar lavage (BAL) for people
with symptoms of VAP plus a new or expanding inﬁltrate on
chest X-ray [13].
Our study concerned with the analysis of VAP studies done
in Egyptian University Hospitals in the last 10 years to de-
scribe the magnitude of the problem of VAP in Egypt, and also
to explore its predictors and its most common causative
organisms.
Depending on the data, incidence in these ICUs ranges
from 16% to 75%. In comparison with incidence of VAP
World Wide, 10–28% and in the United States 9–27%
[20], incidence of VAP in our ICUs is about 2.5 times more.
The highest incidence, 75% was noted in Ain Shams Univer-
sity and the lowest incidence, 16% was in Alexandria Uni-
versity, while the incidence in Mansoura University was
22.6%.
As regards the risk factors of VAP we found four descriptive
cross sectional studies by Tayel [5], Shalaby [10], Seweilam [9]
and Abd El-Kader [1] that explored the most common risk fac-
tors in their ICUs (in neonates, childhood and adult). Tayel [5]
concluded the most common risk factors that were host related
as low Gestational age, low birth weight, leukopenia, thrombo-
cytopenia, high CRP, and metabolic acidosis. Shalaby [10] con-
cluded their risk factors, host related risk factors as nasal
endotracheal intubation, re-intubation and prior antibiotic
use, personal related risk factors as colonized health care work-
ers with MRSA and device related risk factors as contaminated
ICU environment with lack of infection control measures.
Sweilam [9] concluded risk factors which were host related asprior antibiotic use, duration of mechanical ventilation, reintu-
bation, use of antacids and H2 blocker, corticosteroids use and
coma. While Abd El-Kader [1] mentioned two host related risk
factors; long duration of ICU admission and long duration of
mechanical ventilation. In comparison with studies concluding
the common risk factors of VAP, a Logistic regression analysis
done by Lippincott and Wilkins (2011) identiﬁed three factors
signiﬁcantly associated with ventilator-associated pneumonia
caused by any one of the multidrug-resistant bacterial strains:
emergency intubation, aspiration and Glasgow coma score of
nine or less. While Grammatikos et al. [13] concluded the Risk
factors for infection with an MDR strain; ventilation for more
than 5 days, recent hospitalization (last 90 days), residence in a
nursing home, treatment in a hemodialysis clinic, and prior
antibiotic use (last 90 days).
As regards the causative organisms, the etiological agents
of VAP may differ according to patients, units, hospitals or
countries. The main epidemiological patterns may not only
vary from unit to unit, but also in a given unit over the course
of time and this is true for their associated susceptibility pat-
terns. Thus, reported differences can frequently be explained
by local speciﬁcities [16].
In our study, there were 17 studies involved in the causative
organisms of VAP; 10 in Alexandria, three in Mansoura, three
in Ain Shams and 1 in Tanta Universities. Most of them were
cross sectional studies with some interventional, case control
and cohort prospective studies.
The most common causative organisms of VAP ﬁnally
from all the studies were P. aerogenosa, Klebsiella, E. coli,
Staph. aureus, Acinetobacter, Candida and Proteus. Other
organisms found were; methicillin-resistant Staph. aureus
(MRSA), Streptococci, Polymicrobial, Coagulase Neg. Staphy-
lococci, vancomycin-resistant S. aureus (VRSA), oxacillin sen-
sitive Staph. aureus (OSSA), oxacillin resistant S. aureus
(ORSA), Citrobacter, methicillin sensitive Staph. aureus
(MSSA), Gm ve NLF, Enterobacter aerogenosa, Diphtheria
and Enterococcus fecalis.
From these results we noted that the most common causa-
tive organisms are mostly MDR pathogens and non MDR
pathogens are less likely as a cause. These were in agreement
with Loscalzo et al. [14] who concluded MDR pathogens as
Table 3 Causative organisms of VAP in Egyptian Universities.
Causative organisms Specimens Design Age group No. of
patients
Authors University
Direct smear
1. Gram +ve cocci 43.8%
2. Gram ve 40.6%
3. Mixed infection 15.6%BACTEC
9050 aerobic culture
1. Staphylococci 40.6%
2. Gram negative 46.9%
3. Mixed +ve and ve 12.5%BAL
culture by ordinary methods
1. Staphylococci 37%
2. Gram negative bacilli 43.8%
3. Mixed growth 15.6%
4. Anthracoid 3.1%
BAL Descriptive
cross sectional
study
18–60 ys. 32 Moawad [18] Mansoura
1. Pseudomonas aerogenosa 21.05%
2. Staph. aureus 15.8%
3. Polymicrobial 15.8%
4. Gm negative organisms 26.3%
ETA Descriptive
cross sectional
study
1 month–18 ys. 97 Abd El-Kader [1] Mansoura
61.1% positive for organisms.
1. Klebsiella pneumoniae 30.9%
2. Pseudomonas aerogenosa 22.5%
3. Staphylococcus aureus 21.2%
4. E. coli 12.8%
5. Proteus spp. 9.8%
6. Citrobacter spp. 2.8%
ETA Descriptive
cross sectional
study
1–85 ys. 95 Seweilam [9] Mansoura
1. Enterobacter spp. 25%
2. Pseudomonas spp. 22.5%
3. Staph. aureus 15%
4. Coagulase ve Staph 7.5%
5. Candida spp. 10%
6. Citrobacter spp. 5%
7. Klebsiella spp. 5%
8. E. coli 5%
9. Erwinia spp. 5%
BAL and
ETA
Descriptive
cross sectional
study
1–8 ys. 40 Abd El-Kader [2] Ain Shams
CHX group
1. Klebsiella 3.29%
2. Pseudomonas 2.19%
3. Candida 0.36%
4. Proteus 0.71%
5. OSSA 0.36%
6. ORSA 1.44%Sewak group
1. Klebsiella 0.71%
2. Pseudomonas 1.09%
3. Candida 0.36%
4. Proteus 0.36%
5. OSSA 0.36%
6. ORSA 0.36%
ETA Interventional
study
5–70 ys. 40; * Sewak
vs. CHX
Abd El-wahed
[11]
Alexandria
1. Pseudomonas 41.7%
2. E. coli 4.2%
3. Proteus 12.5%
4. Klebsiella 8.3%
5. Acinetobacter 4.2%
6. Streptococci 18.8%
7. MSSA 6.3%
8. MRSA 6.3%
9. VRSA 2.1%
QEA Descriptive
cross sectional
study
2–80 ys. 48 Khalil [15] Alexandria
(continued on next page)
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Table 3 (continued)
Causative organisms Specimens Design Age group No. of
patients
Authors University
Control group
1. Klebsiella 20%
2. Pseudomonas 6.7%
3. Gm ve NLF 13.3%
4. Acinetobacter 13.3%
5. ORSA 0.0%
6. OSSA 6.7%
7. E. coli 20%
8. Streptococcus pneumonia 20%
Hydrocortisone group
1. Klebsiella 6.7%
2. Pseudomonas 6.7%
3. Gm ve NLF 20%
4. Acinetobacter 13.3%
5. ORSA 6.7%
6. OSSA 6.7%
7. E. coli 26.7%
8. Streptococcus pneumonia 13.3%
QEA Intervention
study
28–85 ys. 30 @15: control
group and 15:
Hydrocortison
group
Morsi (2008) Alexandria
1. Pseudomonas aerogenosa 33.3%
2. Staph. aureus 26.2%
3. Klebsiella pneumoniae 16.7%
4. Co-agulase Neg. Staph. 7.1%
5. Polymicrobial 7.1%
6. Citrobacter 2.4%
7. Proteus 2.4%
8. Candida 2.4%
9. Streptococcus pneumoniae 2.4%
ETA Case control
study
1 day–18 ys. 52 (42: cases, 10:
control)
Shalaby [16] Tanta
Gram +ve organisms
1. Saline group: 57.2% vs.
2. CHX group: 21.4% vs.
3. CHX/COL group: 21.4%Gram –
ve organisms
1. Saline group: 54.5% vs.
2. CHX group 36.4% vs.
3. CHX/COL group 18.1%
Throat swab Interventional
study.
19–75 ys. 75 #3 groups:
- Saline
- CHX
- CHX/COL
Soliman [9] Alexandria
1. Klebsiella 43.75%
2. Acinetobacter 31.25%
3. Staphylococcus aureus 12.5%
4. Enterococci 12.5%
BAL Cohort
prospective
study
Mean age; 16.6 ± 20.5 month 252 Abdel-
Gawad
et al. [10]
Ain Shams
1. Candida spp. 23.3%
2. Pseudomonas aerogenosa
21.6%
3. Polymicrobial 20%
4. Staphylococcus aureus 16%
5. Acinetobacter spp. 8.3%
6. Proteus spp. 6.6%
7. Klebsiella spp. 6.6%
8. E. coli spp. 5%
9. Coagulase-negative Staphylo-
cocci 1.6%
10. Diphtheroids 1.6%
ETA Descriptive
cross sectional
study
1.5–85 ys. 60 VAP cases vs. 30
non VAP cases
Asser [12] Alexandria
1. Klebsiella 28.5%
2. Pseudomonas 14.2%
3. Acinetobacter 12.3%
4. E. coli 4.1%
5. Polymicrobial 10.2%
6. MRSA 4.1%
7. Enterococcus fecalis 4.1%
8. Staphylococcus aureus 2%
9. Candida 14.2%
ETA Descriptive
cross sectional
study
Neonates
(2–8 days)
110 Tayel [5] Alexandria
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Table 3 (continued)
Causative organisms Specimens Design Age group No. of
patients
Authors University
1. Pseudomonas species 45.0%
2. Methicillin sensitive Staphylococcus species 5.0%
3. Acinetobacter species 20.0%
4. Klebsiella aerogenes 10.0%
5. E. coli 20.0%
BAL Descriptive
cross sectional
study
16–56 ys. 20 Zidan [22] Alexandria
1. Candida 23.3%
2. Pseudomonas aerogenosa 21.6%
3. Staph. aureus 16.0%
4. Acinetobacter 8.3%
5. Proteus spp. 6.6%
6. Klebsiella 6.6%
7. E. coli 5.0%
8. Co-agulase Neg. Staph. 1.6%
9. Diphtheroid 1.6%
ETA Case control
study
18–85 ys. 90 (60: cases,
30: control)
Mokhless et al.
[19]
Alexandria
1. Acinetobacter 51.5%
2. P. aerogenosa 18.2%
3. Klebsiella pneumonia 15.1%
4. E. coli 6.1%
5. Enterobacter aerogenes 3%
6. S. aureus 15.1%
7. Coagulase ve Staph. 15.1%
8. Candida 12.1%
BAL Descriptive
cross sectional
study
1–75 ys. 206 Abou El-Abbas
[6]
Alexandria
HME group
1. Pseudomonas 23.1%
2. Streptococci 7.7%
3. MRSA 10.3%
4. Contamination 15.4%
5. Acinetobacter 11.5%
6. Candida 7.7%
7. Klebsiella 11.5%
8. Polymicrobial 3.8%
9. E. coli 3.8%
10. Staphylococci 0.0%HH group
1. Pseudomonas 27.6%
2. Streptococci 0.0%
3. MRSA 10.3%
4. Contamination 17.2%
5. Acinetobacter 13.8%
6. Candida 3.4%
7. Klebsiella 13.8%
8. Polymicrobial 3.4%
9. E. coli 3.4%
10. Staphylococci 6.9%
Sputum Intervention
study
16–77 ys. 60; 30 (heat
moisture
exchanger group)
and 30 (heated
humidiﬁer group)
Khamis [7] Alexandria
BAL (single species)
1. E. coli 8.6%
2. Acinetobacter species 2.9%
3. VRSA 2.9%
4. MRSA 31.4%
5. Klebsiella 11.4%
6. Staphylococcus aureus 2.9%
7. Pseudomonas 11.4%(Mixed infection)
1. Klebsiella spp. and Candida spp. 2.9%
2. Klebsiella spp. and methicillin-resistant Staphylo-
coccus aureus 5.7%
3. Klebsiella spp. and S. aureus 5.7%
4. Klebsiella spp. and Pseudomonas spp. 2.9%
5. Pseudomonas spp. and Candida spp. 2.9%
6. No growth 8.6%ETA (single species)
1. E. coli 7%
2. MRSA 16.3%
3. Candida 2.3%
4. Klebsiella 7%
5. Staphylococcus aureus 4.6%
6. Pseudomonas 9.3%(Mixed species)
BAL and
ETA
Descriptive
cross sectional
study
18–75 ys. 107 Mohammed [8] Ain Shams
(continued on next page)
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Table 3 (continued)
Causative organisms Specimens Design Age group No. of
patients
Authors University
1. Klebsiella and MRSA 9.3%
2. Klebsiella and S. aureus 4.6%
3. Klebsiella and Pseudomanas 2.3%
4. Klebsiella and E. coli 2.3%
5. Klebsiella and Candida 2.3%
6. Pseudomonas and Staphylococcus aureus
2.3%
7. Candida and MRSA 4.6%
8. E. coli and VRSA 2.3%
9. E. coli and Staphylococcus aureus 2.3%
10. No growth 20.9%
HME group, heat moisture exchanger; HH group, heated humidiﬁer.
Control group, included 15 patients received conventional therapy.
Hydrocortisone group, included 15 patients received conventional therapy the same as the control group plus the hydrocortisone therapy.
24 A. Fathy et al.the most common causative organisms of VAP such as E. coli,
MSSA, Klebsiella, Proteus, Haemophilus inﬂuenzae and
Enterobacteriaceae.
In identifying organisms in early onset and late onset VAP,
Abd El-Kader [2] conducted a study at the Pediatric Intensive
Care Unit (PICU) in Children’s Hospital at Ain Shams Uni-
versity and concluded that S. aureus was the most common
microorganism isolated in early onset VAP while Pseudomonas
species and Enterobacteriaceae species were the most common
organisms isolated in late onset VAP.
As regards the role of distinct pathogens, including
Legionella spp., anaerobes, fungi and viruses, the so-called
commensals, were frequently addressed as nonpotentially
pathogenic micro-organisms (non-PPM). Asser [12] con-
cluded that these pathogens may be more common than orig-
inally thought, but their role has not been settled and this
was in agreement with Marik et al. [17] who draw the atten-
tion toward the possibility of these agents as being causative
organisms for VAP that clinicians should take into account
such microorganisms and consider them during empirical
therapy.
We faced some difﬁculties during this work in collecting
materials such as unavailability of electronic data base as
studies found cited on websites were only the title of the
study with the name of the author and abstract of the study.
Moreover we faced some vague study design, small sample
size, different study designs preventing us from getting statis-
tical result from data and controversy between study content
and study design, We try hard to collect as much as possible
from the studies done in VAP to get speciﬁc, universal, clear
and approved data for preventing the problem of VAP,
decreasing its magnitude and enriching its management, but
study limitations did not give us a chance of that hopeful tar-
get and force us to get individual results of the three param-
eters of our study; incidence, risk factors and most common
causative organisms of VAP one by one. So we recommend
to establish a large-scale multi center national study to ex-
plore incidence of VAP, all possible risk factors (whether pre-
ventable or non preventable), causative organisms, mortality
due to VAP and its economic aspect, and also to develop
an indexing system for all these in Egyptian Universities with
key words according to MeSH.References
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